Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 642 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

642 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

642 programs

Clinical programs

Page 2 of 14

  1. CS1003-305

    Lacuna Pharma Pty Ltd

    Unresectable advanced hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  2. CX842A2301

    Lacuna Pharma Pty Ltd

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  3. CX842A2303

    Lacuna Pharma Pty Ltd

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  4. Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  5. Carbetocin Nasal Spray

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  6. Cemdisiran, Pozelimab

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  7. Cidofovir, Brincidofovir

    Lacuna Pharma Pty Ltd

    Adenovirus viremia

    phase 3 small molecule active

    1 trial

  8. D8227C00001

    Lacuna Pharma Pty Ltd

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  9. DAY101-002

    Lacuna Pharma Pty Ltd

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  10. DCC-2618-03-002

    Lacuna Pharma Pty Ltd

    Patients with Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  11. DCC-3014-03-001

    Lacuna Pharma Pty Ltd

    Tenosynovial Giant Cell Tumor

    phase 3 small molecule active

    1 trial

  12. DCR-PHXC-301

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 3 other active

    1 trial

  13. DHM/EPH/01/2022

    Lacuna Pharma Pty Ltd

    Menopause, sleep disorders in the postmenopausal period

    phase 3 small molecule active

    1 trial

  14. DP-10027

    Lacuna Pharma Pty Ltd

    post-operative nausea and vomiting in pediatric patients

    phase 3 small molecule active

    1 trial

  15. DTX301-CL301

    Lacuna Pharma Pty Ltd

    Late-onset Ornithine transcarbamylase (OTC) deficiency

    phase 3 small molecule active

    1 trial

  16. DTX401-CL301

    Lacuna Pharma Pty Ltd

    Glycogen Storage Disease Type Ia (GSDIa)

    phase 3 small molecule active

    1 trial

  17. DUO2025_01

    Lacuna Pharma Pty Ltd

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    phase 3 small molecule active

    1 trial

  18. DZ2024B0002

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  19. EFC17093

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  20. EP0162

    Lacuna Pharma Pty Ltd

    Stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  21. EP0165

    Lacuna Pharma Pty Ltd

    Treatment of stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  22. EP0224

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy, Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  23. Epidyolex 100 mg/ml oral solution

    Lacuna Pharma Pty Ltd

    Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome

    phase 3 small molecule active

    1 trial

  24. Etrasimod Arginine Blue

    Lacuna Pharma Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  25. Eylea 40 mg/mL solution for injection in a vial

    Lacuna Pharma Pty Ltd

    Retinopathy of prematurity (ROP)

    phase 3 small molecule active

    1 trial

  26. FAT EMULSIONS , Triheptanoin

    Lacuna Pharma Pty Ltd

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 3 small molecule active

    1 trial

  27. FDY-5301-302

    Lacuna Pharma Pty Ltd

    Anterior ST-Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  28. FLECA-ED

    Lacuna Pharma Pty Ltd

    Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%

    phase 3 small molecule active

    1 trial

  29. FMGX-CS-302

    Lacuna Pharma Pty Ltd

    Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

    phase 3 small molecule active

    1 trial

  30. FUR-05-24

    Lacuna Pharma Pty Ltd

    Bacterial vaginosis

    phase 3 small molecule active

    1 trial

  31. FpA-AS-30093

    Lacuna Pharma Pty Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  32. FpA-AS-30094

    Lacuna Pharma Pty Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  33. GLUCOTHERA PLUS

    Lacuna Pharma Pty Ltd

    End-stage Kidney Disease

    phase 3 small molecule active

    1 trial

  34. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  35. GTX-102-CL302

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  36. HQP1351AG301

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  37. HQP1351CG301

    Lacuna Pharma Pty Ltd

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  38. HSK3486-309

    Lacuna Pharma Pty Ltd

    General anaesthesia

    phase 3 small molecule active

    1 trial

  39. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  40. INZ-701, INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  41. IP-001-18

    Lacuna Pharma Pty Ltd

    End-Stage Kidney Disease

    phase 3 small molecule active

    1 trial

  42. Impetine® 20mg/g Gel, Bactroban 20 mg/g pomada

    Lacuna Pharma Pty Ltd

    Impetigo

    phase 3 small molecule active

    1 trial

  43. JNJ-67896062, JNJ-67896062

    Lacuna Pharma Pty Ltd

    Pediatric pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  44. JR-141

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  45. JR-141-GS31

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  46. JX10002

    Lacuna Pharma Pty Ltd

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  47. JZP258

    Lacuna Pharma Pty Ltd

    Narcolepsy

    phase 3 small molecule active

    1 trial

  48. KT-US-473-0133

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.